SCHEMBL2896550

SCHEMBL2896550

O=C(NC(NC(=O)c1ncc2nc(-c3cc4ccccc4s3)sc2c1O)C(=O)O)c1ncc2nc(-c3cc4ccccc4s3)sc2c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.38
STK17B O94768 1/20 0.37
CAMKK1 Q8N5S9 1/20 0.37
AURKB Q96GD4 1/20 0.37
CAMKK2 Q96RR4 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
STK17A Q9UEE5 1/20 0.37
TBK1 Q9UHD2 1/20 0.35
IKBKB O14920 4/20 0.34
CHUK O15111 1/20 0.34
IKBKG Q9Y6K9 1/20 0.34
PIN1 Q13526 2/20 0.34
HDAC2 Q92769 2/20 0.34
GRIN2B Q13224 1/20 0.34
APP P05067 1/20 0.33
ACLY P53396 1/20 0.33
MAOA P21397 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898413 0.84 EGLN1 (0.38) EGLN1
SCHEMBL2886853 0.84 EGLN1 (0.57) EGLN1STK17BCAMKK1AURKBCAMKK2
SCHEMBL2893699 0.83 EGLN1 (0.41) EGLN1MAOAHDAC1
SCHEMBL2897617 0.82 AKR1C3 (0.37) EGLN1
SCHEMBL2896782 0.80 EGLN1 (0.41) EGLN1HDAC2APPMAOA
SCHEMBL2898194 0.78 KDM4E (0.38) EGLN1ADORA1
SCHEMBL2886005 0.77 JAK2 (0.48) STK17BCAMKK1AURKBCAMKK2PIM2
SCHEMBL2889352 0.74 EGLN1 (0.43) EGLN1MAOAHDAC8
SCHEMBL1977591 0.69 EGLN1 (0.41) EGLN1MAOAHDAC6
SCHEMBL2882130 0.67 EGLN1 (0.58) EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 EGLN1 5/4885STK17B 492/4885CAMKK1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.